ArticleFrontiers in nutrition2025
Therapeutic effects of a combination of
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune and inflammatory mechanisms in asthma: insights into epigenetic modifications.Frontiers in immunology · 2025Pooled it
- Beyond Polysaccharides: Multifunctional Roles of Plant-Derived Conjugates in Sensory Enhancement and Food Quality Improvement.Comprehensive reviews in food science and food safety · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic asthma involves chronic inflammation, airway remodeling, and hyperresponsiveness. Inhaled corticosteroids combined with long-acting β2 agonists are effective; however, some patients experience side effects, highlighting the need for safer natural alternatives suitable for long-term use. Methods: The therapeutic efficacy of the Q/SC extract was evaluated in an ovalbumin (OVA)-induced allergic airway inflammation model. After euthanasia, we assessed cell counts, cytokine expression in the bronchoalveolar lavage fluid (BALF), blood immunoglobulin (Ig) E levels, inflammatory cell infiltration, mucus production in the lung tissue, and the expression of protein and cytokine. Results: A high-concentration Q/SC extract significantly reduced total cell and eosinophil counts, cytokine expression in BALF, and serum IgE levels. Furthermore, it reduced the expression of type 2 cytokines (IL-4, IL-5, IL-13) and inducible nitric oxide synthase in lung tissue. The extract also attenuated inflammatory cell infiltration and mucus production while inhibiting the STAT6 signaling pathway. Conclusion: A high concentration of Q/SC extract effectively alleviates allergic airway inflammation by reducing eosinophilic inflammation, type 2 cytokine secretion, and mucus hyperproduction. This suggests that it could be a potential remedy for managing allergic airway inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.